[go: up one dir, main page]

DE60237704D1 - Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden - Google Patents

Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden

Info

Publication number
DE60237704D1
DE60237704D1 DE60237704T DE60237704T DE60237704D1 DE 60237704 D1 DE60237704 D1 DE 60237704D1 DE 60237704 T DE60237704 T DE 60237704T DE 60237704 T DE60237704 T DE 60237704T DE 60237704 D1 DE60237704 D1 DE 60237704D1
Authority
DE
Germany
Prior art keywords
hiv
antibodies
antibody fragments
nucleic acids
env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237704T
Other languages
English (en)
Inventor
Dimiter S Dimitrov
Maxime Moulard
Xiadong Xiao
Yuuei Shu
Sanjay K Phogat
Mei-Yun Zhang
Dennis Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GOVERNMENT OF US SECRETARY
Scripps Research Institute
US Department of Health and Human Services
Original Assignee
GOVERNMENT OF US SECRETARY
Scripps Research Institute
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GOVERNMENT OF US SECRETARY, Scripps Research Institute, US Department of Health and Human Services filed Critical GOVERNMENT OF US SECRETARY
Application granted granted Critical
Publication of DE60237704D1 publication Critical patent/DE60237704D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C07K16/1145—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60237704T 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden Expired - Lifetime DE60237704D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32970901P 2001-10-16 2001-10-16
PCT/US2002/033165 WO2003033666A2 (en) 2001-10-16 2002-10-16 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes

Publications (1)

Publication Number Publication Date
DE60237704D1 true DE60237704D1 (de) 2010-10-28

Family

ID=23286644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237704T Expired - Lifetime DE60237704D1 (de) 2001-10-16 2002-10-16 Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden

Country Status (7)

Country Link
US (2) US7223844B2 (de)
EP (1) EP1450857B1 (de)
AT (1) ATE481109T1 (de)
AU (1) AU2002337885B1 (de)
CA (1) CA2463931A1 (de)
DE (1) DE60237704D1 (de)
WO (1) WO2003033666A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951947B2 (en) 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
EP1450857B1 (de) 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP2036985A1 (de) * 2002-04-09 2009-03-18 Nationwide Children's Hospital, Inc. Antikörpergentransfer und rekombinantes AAV dafür
EP1504034B1 (de) * 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper
EP1554392A4 (de) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
EP1627046A4 (de) * 2003-05-06 2008-02-13 Scripps Research Inst Bindungsmoleküle mit domänenaustausch, verwendungsverfahren und herstellungsverfahren
WO2006071206A2 (en) * 2003-09-29 2006-07-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulins whith potent and broad antiviral activity
EP1735453A2 (de) 2004-03-12 2006-12-27 The Scripps Research Institute Fluoreszenz-signale abgebende biosensor-moleküle und farbstoffe in lebenden zellen zum nachweis und zur quantifizierung von protein aktivitäten
WO2005111621A2 (en) * 2004-04-16 2005-11-24 Uab Research Foundation Molecular scaffolds for hiv-1 epitopes
US20080038280A1 (en) * 2004-10-14 2008-02-14 Government Of The United States Of America A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines
WO2006091455A2 (en) 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008037419A1 (en) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Antibodies against ccr5 and uses thereof
EP2073840A4 (de) * 2006-10-23 2010-10-27 Progenics Pharm Inc Modifizierte gp140-hüllpolypeptide von hiv-1-isolaten, zusammensetzungen, stabilisierten trimeren komplexen und ihre verwendungen
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
EP2609111B1 (de) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispezifische antikörper die ein disulfid-stabilisiertes fv enthalten
KR101612999B1 (ko) * 2010-08-24 2016-04-15 로슈 글리카트 아게 활성화가능 이중특이적 항체
EP2622090B1 (de) 2010-09-27 2019-06-19 Sangamo Therapeutics, Inc. Zusammensetzungen zur hemmung des eindringens von viren in zellen
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
ES2732213T3 (es) 2011-05-21 2019-11-21 Macrogenics Inc Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
SG10201705245TA (en) 2013-03-14 2017-07-28 Macrogenics Inc Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
JP6516740B2 (ja) * 2013-08-02 2019-05-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
JP2017501970A (ja) * 2013-12-10 2017-01-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 薬学的活性エンティティのマルチサブユニット構造への標的特異的送達のためのマルチサブユニット構造のサブユニットの結合ドメインの使用
JP6533534B2 (ja) 2014-02-14 2019-06-19 マクロジェニクス，インコーポレーテッド 膠芽腫の治療に使用するための組成物及びその使用
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2017387041B2 (en) 2016-12-27 2024-12-12 California Institute Of Technology Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
EP3762033A4 (de) * 2018-03-09 2021-12-08 Atreca, Inc. Anti-hiv-antikörper
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2024097957A1 (en) * 2022-11-03 2024-05-10 Duke University Novel antibodies for hiv and methods of making and using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU3662293A (en) 1992-02-10 1993-09-03 Progenics Pharmaceuticals, Inc. A method of using cd4-containing molecules to substantially reduce the risk of occupational hiv transmission
CA2145757A1 (en) 1992-09-30 1994-04-14 Dennis R. Burton Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US5925741A (en) 1992-12-31 1999-07-20 Ramot University Authority For Applied Research And Industrial Development Ltd. Antibodies directed against binding-associated epitopes
JPH08510246A (ja) 1993-05-07 1996-10-29 アクゾ・ノベル・エヌ・ベー Ｈｉｖ免疫原性複合体
EP0724651B1 (de) 1993-10-19 2008-08-20 The Scripps Research Institute Synthetische humane neutralisierende monoklonale antikörper gegen hiv
WO1996015273A1 (en) 1994-11-10 1996-05-23 The Scripps Research Institute Method for identifying protective antigens for eliciting neutralizing antibodies
IL132596A0 (en) 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
WO1999024465A1 (en) 1997-11-10 1999-05-20 Dana-Farber Cancer Institute Stabilized primate lentivirus envelope glycoproteins
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
AU2604200A (en) 1999-01-08 2000-07-24 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
EP1161455B1 (de) 1999-03-16 2008-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion
PT2067788E (pt) 1999-05-18 2015-10-29 Dyax Corp Bibliotecas de fragmentos fab e métodos para a sua utilização
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
CA2423127A1 (en) 2000-09-22 2002-03-28 Duke University Immunogen comprising ligand bound hiv envelope protein
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10123041A1 (de) 2001-05-11 2002-11-28 Tobias Heintges Humane hochaffine Antikörperfragmente gegen essentielle Proteine von Hepatitis-C-Virus
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1450857B1 (de) 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
EP1554392A4 (de) 2002-05-06 2007-08-08 Us Gov Health & Human Serv Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken
EP1504034B1 (de) 2002-05-06 2012-12-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identifikation neuer breitkreuzreaktiver hiv-1-neutralisierender humaner monoklonaler antikörper

Also Published As

Publication number Publication date
EP1450857A4 (de) 2006-01-18
WO2003033666A3 (en) 2004-06-24
AU2002337885B1 (en) 2003-04-28
US7378093B2 (en) 2008-05-27
WO2003033666A2 (en) 2003-04-24
US20040259075A1 (en) 2004-12-23
CA2463931A1 (en) 2003-04-24
US20070212349A1 (en) 2007-09-13
EP1450857A2 (de) 2004-09-01
ATE481109T1 (de) 2010-10-15
EP1450857B1 (de) 2010-09-15
US7223844B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
DE60237704D1 (de) Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
WO2005000244A3 (en) Methods and compositions for treating rheumatoid arthritis
EP2400021A3 (de) Verfahren und Zusammensetzungen auf ErbB3-Basis zur Behandlung von Neoplasmen
AU9399501A (en) Therapeutic antibodies
WO2003048083A3 (en) Antibodies against monocyte chemotactic proteins
EP2062917A3 (de) Antikörper für einen Erythropoetin-Rezeptor und Verwendungen damit
DE60219801D1 (de) KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
ATE414725T1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
WO2003106498A3 (en) Ox40 (=cd134) receptor agonistic and therapeutic use
MA28982B1 (fr) Anticorps antagonistes de il-17
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
WO2004083249A3 (en) Antibodies against human il-21 receptor and uses therefor
PE20071055A1 (es) Anticuerpos anti mn
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
TW200612921A (en) Chemical compounds
TW200619217A (en) Chemical compounds
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
TW200612935A (en) Chemical compounds
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
Walker et al. High-throughput B cell epitope determination by next-generation sequencing
WO2022081460A8 (en) Biosynthetic materials and methods for multidirectional biotransportation
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
DK1567018T3 (da) Fremgangsmåde til at forbedre immunfunktionen hos pattedyr ved anvendelse af lactobacillus reuteri stammer